AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

22.360

-0.090-0.40%

Volume:263.76K

Turnover:6.04M

Market Cap:2.83B

PE:96.09

High:23.220

Open:23.200

Low:22.270

Close:22.450

52wk High:23.760

52wk Low:11.000

Shares:126.64M

Float Shares:108.39M

Volume Ratio:3.58

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.233

EPS(LYR):0.233

ROE:8.67%

ROA:3.66%

PB:8.37

PE(LYR):96.09

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies+1.47%

Capital Flow

Inflow:

Outflow:

News

Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug

MT Newswires Live

Neuren Pharmaceuticals - European Commission Grants Marketing Authorization for Daybu (Trofinetide)

THOMSON REUTERS

ASX Biggest Gainers

MT Newswires Live

Neuren Pharmaceuticals (ASX:NEU) Is Up 26.3% After Record DAYBUE Sales and Upgraded 2026 Royalties

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.etasphere.com/stock/NEU.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":22.36,"timestamp":1787618794113,"preClose":22.45,"halted":0,"volume":263762,"delay":0,"changeRate":-0.004008908685968813,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":0.2327,"marketStatus":"Trading","change":-0.09,"latestTime":"08-25 10:47:14 AEST","open":23.2,"high":23.22,"low":22.27,"amount":6036540,"amplitude":0.042316,"askPrice":22.4,"askSize":89,"bidPrice":22.38,"bidSize":95,"shortable":3,"etf":0,"ttmEps":0.2327,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787637600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":22.45,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":3.584328,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NEU.AU","preClose":22.45,"auctionPrice":23.2,"auctionVolume":116500,"auctionTime":1787615954579,"referenceTime":1787567403094,"auction":1,"marketStatus":"盘前竞价","timestamp":1787615954579}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"3.66%","roe":"8.67%","lyrEps":0.2327,"volumeRatio":3.584328,"shares":126639526,"dividePrice":0,"high":23.22,"amplitude":0.042316,"preClose":22.45,"low":22.27,"week52Low":11,"pbRate":"8.37","psRate":"43.80","week52High":23.76,"institutionHeld":0,"latestPrice":22.36,"committee":0.032609,"eps":0.2327,"divideRate":0,"volume":263762,"delay":0,"ttmEps":0.2327,"open":23.2,"prevYearClose":18.61,"prevWeekClose":22.46,"prevMonthClose":18,"prevQuarterClose":17.75,"fiveDayClose":23.04,"twentyDayClose":17.05,"sixtyDayClose":14.21,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662204730","title":"Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662204730","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662204730?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:10","pubTimestamp":1787616632,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said the European Commission gave marketing authorization for Daybu, or trofinetide, for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older to its exclusive global licensee for trofinetide, Acadia Pharmaceuticals, according to a Tuesday Australian bourse filing.Daybu is now authorized to be marketed in all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway, per the filing.Under the companies' license agreement, for Europe, Neuren is entitled to receive $35 million following first commercial sale, potential sales milestone payments of up to $170 million on achievement of escalating annual net sales thresholds, and tiered royalties from mid-teens to low-20s percentage of net sales.Acadia earlier said that a commercial launch in Germany is expected in the December quarter.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7096","BK7508","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662019942","title":"Neuren Pharmaceuticals - European Commission Grants Marketing Authorization for Daybu (Trofinetide)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662019942","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662019942?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:31","pubTimestamp":1787610678,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUEC7XGBB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657693426","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2657693426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657693426?lang=en_us&edition=fundamental","pubTime":"2026-08-07 11:27","pubTimestamp":1786073273,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest gains on Friday.Mineral 260 : +10%, AU$0.80Light & Wonder CDI : +7%, AU$126.43Iluka Resources : +7%, AU$7.25Pilbara Minerals : +6%, AU$4.57Telix Pharmaceuticals : +6%, AU$15.89Liontown Resources : +6%, AU$1.14Predictive Discovery : +6%, AU$0.77West African Resources : +5%, AU$3.49James Hardie Industries : +5%, AU$42.78Neuren Pharmaceuticals : +4%, AU$22.52","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7504","BK7506","TLX.AU","NEU.AU","JHX.AU","BK7044","LTR.AU","LNW.AU","BK7096","BK7067","ILU.AU","BK7507","BK7078","WAF.AU","PDI.AU","PLS.AU","BK7095","BK7104","MI6.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657861486","title":"Neuren Pharmaceuticals (ASX:NEU) Is Up 26.3% After Record DAYBUE Sales and Upgraded 2026 Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2657861486","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657861486?lang=en_us&edition=fundamental","pubTime":"2026-08-06 13:42","pubTimestamp":1785994942,"startTime":"0","endTime":"0","summary":"In the second quarter of 2026, Neuren Pharmaceuticals reported record DAYBUE net sales of US$125 million, its highest quarterly result since launch, driven by strong uptake of the new DAYBUE STIX powder formulation in the US and supported by positive regulatory progress in Europe.\nThis sales performance led Neuren to upgrade its full-year 2026 royalty income projections, underscoring how formulation innovation and advancing European approvals are influencing its revenue outlook.\nWe’ll now...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-up-263-after-record-daybue","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-up-263-after-record-daybue","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NEU.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.014707}]}}